BioCryst Pharmaceuticals (BCRX) presents a deeply negative liquidation posture as of March 31, 2026, with reported stockholders' equity of negative $553.8 million. Under liquidation-value haircuts, recovery to equity deteriorates further. Total assets of $465.1 million carry significant intangible and non-recoverable components: cash and equivalents of $171.6 million recover at par; available-for-sale investments (short-term $66.8 million, long-term $20.6 million) recover near par given liquid market instruments; accounts receivable of $109.3 million recovers at approximately 90-95%; inventory net of $6.0 million (plus noncurrent $28.2 million) recovers at roughly 60% given pharmaceutical product specificity; PP&E net of $9.4 million recovers at 50-70%. The dominant balance-sheet event this quarter is the all-stock acquisition of Astria Therapeutics for $489.5 million cash paid net of cash acquired, financed entirely by the new Blackstone Term Loan ($400 million initial draw, net proceeds $395.0 million, accruing at SOFR + 4.50% + possible PIK premium, effective rate 8.47% for Q1 2026). The acquisition was treated as an asset acquisition under ASC 805, with $697.8 million of the consideration allocated to acquired in-process R&D (navenibart) and immediately expensed — producing a GAAP net loss of $721.8 million for the quarter. This IPR&D charge has zero recovery value under the liquidation lens; intangibles receive a 0% haircut. The Blackstone Term Loan adds $395.2 million to the noncurrent liability stack at face value, while royalty financing obligations (RPI/OMERS) remain on the balance sheet and must be settled at face. Total liabilities of $1.019 billion against haircut assets produce a materially negative recovery to equity. The prior filing (10-K, December 31, 2025) reflected no Blackstone debt and no Astria acquisition — the QoQ shift in the liability stack is the single largest change. MFFAIS CLV of negative $431.3 million, LLV of negative $322.0 million, and OLV of negative $316.0 million are directionally consistent with this analysis. The royalty financing obligations are discussed extensively in the MD&A and footnotes but their carrying value is not separately tagged in XBRL as a distinct line item distinct from the broader liabilities aggregate; the filing references this in Note 7 but the tag context does not include a dedicated royalty financing obligation balance tag. Operating cash burn was $61.8 million for the quarter, elevated versus $27.5 million in Q1 2025. The ANDA Paragraph IV challenge on ORLADEYO patents (expiring 2039) constitutes a contingent liability not yet quantifiable, representing additional downside to any recovery scenario.
▼ Community Notes